Inlyta 1 mg, 3 mg, 5 mg, 7 mg Film-coated tablets.
PDF Leaflet Revision Date: 01 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced renal cell carcinoma after prior therapy.
Dosage (summary)
Starting dose: 5 mg twice daily; may increase to 7 mg or 10 mg based on tolerance.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; effective contraception required.
Key Drug Interactions
- CYP3A4/5 inhibitors
- CYP3A4/5 inducers
Contraindications
- Hypersensitivity to axitinib
- Pregnancy
- Lactation
- Children < 18 years
- Severe hepatic impairment
- Uncontrolled hypertension
Common side effects
- Diarrhoea
- Hypertension
- Fatigue
- Nausea
- Proteinuria
Counselling Points
- Monitor blood pressure regularly
- Avoid pregnancy
- Report any signs of bleeding or cardiac issues
Serious warnings
- Cardiac failure events
- Hypertension
- Thyroid dysfunction
- Gastrointestinal perforation
Important Disclaimer
The Inlyta 1 mg, 3 mg, 5 mg, 7 mg Film-coated tablets. professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
